Abstract: A bilateral compensatory increase of basal ganglia (BG) gray matter value (GMV) was recently demonstrated in asymptomatic Parkin mutation carriers, who likely have an increased risk to develop Parkinson's disease (PD). We hypothesized BG morphological changes in symptomatic Parkin mutation carriers (sPARKIN-MC) and idiopathic PD patients (iPD) after the occurrence of PD symptoms, reflecting the breakdown of compensatory mechanisms. Nine sPAR-KIN-MC, 14 iPD, and 24 controls were studied clinically and with voxel-based morphometry. Analysis of variance revealed mainly BG decrease of GMV in sPARKIN-MC and to a lesser extent in iPD. However, a slight increase in GMV was also found in the right globus pallidus externus in sPARKIN-MC and in the right putamen in iPD. This may reflect a structural correlate of functional compensation that can only partially be maintained when nigrostriatal neurodegeneration becomes manifest. Simple regression analyses with the UPDRS-III and disease duration score revealed a distinct more bilateral linear decrease of BG GMV in sPARKIN-MC than in iPD that may correspond to previous findings showing a symmetric reduction in putaminal 18 F-DOPA-uptake and bilateral manifestation of symptoms in sPARKIN-MC. In symptomatic PD, BG are subject to a progressive atrophy, which gradually increases with disease severity and duration.
Parkinson's disease (PD) is a common, slowly progressive neurodegenerative disorder primarily characterized by rigidity, tremor, and bradykinesia. Although the origin of PD currently remains unknown, in the majority of PD patients (idiopathic PD [iPD] ), a total of about 2-3% of all cases can now be explained by a monogenic cause. Mutations in the Parkin gene are the most common known single factor responsible for early-onset parkinsonism. 1 This monogenic variant is often clinically 2, 3 and pathologically 1, 4 indistinguishable from iPD. Clinical observations, however, suggest that Parkin-associated PD tends to manifest earlier and more symmetric, have a milder course than iPD and better response to levodopa. 3, 5 In PD, motor symptoms are caused by a dysfunction of the cortico-basal-ganglia-loop due to progressive degeneration of nigrostriatal dopaminergic neurons. Correspondingly, positron emission tomography (PET) studies demonstrated in symptomatic Parkin mutation carriers (sPARKIN-MC), as well as in iPD patients, a reduction of the striatal 18-fluorodopa ( 18 F-DOPA) uptake indicating a presynaptic dopaminergic dysfunction. [6] [7] [8] [9] Notably, sPARKIN-MC showed a more sym-metric reduction of 18 F-DOPA uptake 7, 8, 10 and a slower progression in 18 F-DOPA PET than iPD patients. 9 While ample PET data about PD patients are available, 6, 7, 9 the results of MR-morphometric studies regarding the basal ganglia in iPD patients are still scarce and inconsistent: In iPD patient's normal [11] [12] [13] [14] or (partly) decreased [15] [16] [17] [18] gray matter volume (GMV) of the basal ganglia were observed. In more detail, MRI-based studies on patients with advanced PD detected a decreased volume of the putamen 15, 16, 18 and globus pallidus 18 and in a voxel-based morphometry (VBM) study, an atrophy of the head of the left caudate was found. 17 There are no morphometric MRI data on sPARKIN-MC available as yet. However, we recently demonstrated that asymptomatic Parkin mutation carriers (aPARKIN-MC) showed a bilateral increase of striatal GMV. 19 In our aPARKIN-MC, who likely have an increased risk to develop PD and therefore may be regarded as a model for a presymptomatic stage of PD, PET revealed a latent presynaptic dopaminergic dysfunction. This led us propose that the ''hypertrophy'' in the basal ganglia may be a long-term consequence of compensatory mechanisms that successfully counteract the chronic dopaminergic striatal dysfunction. Alternatively, the morphometric changes may be a direct consequence of nigrostriatal dysfunction itself. 19 Thus, the objective of the present study was to investigate the relationship between the severity and duration of motor symptoms in iPD and sPARKIN-MC with the extent and topography of basal ganglia GMV changes as revealed by VBM. Regarding our hypothesis, the initial ''compensatory hypertrophy'' in the basal ganglia should gradually taper off when PD has reached the symptomatic stage of the disease. More specifically, the more severely the patients are affected, the stronger the expected decrease in basal ganglia GMV.
PATIENTS AND METHODS
To address this issue, 9 sPARKIN-MC (two females, mean age: 52.3 6 3.8 years) and 14 iPD patients (eight females, mean age: 50.9 6 1.1 years) were investigated, along with 24 age-and sex-matched controls (11 females, mean age: 52.1 6 1.5 years). The sPAR-KIN-MC and iPD patients were recruited from the outpatient movement disorders clinics at the Department of Neurology, University of Luebeck, in Germany and at the Department of Neurology, Central Hospital and Genetic Medicine, EURAC-Research, Bolzano-Bozen in Italy where the patients have been diagnosed and are followed up on a regular basis. All patients traveled to the study center in Luebeck and were personally interviewed and clinically examined using a standardized protocol. The motor section of the Unified Parkinson's Disease Rating Scale (UPDRS-III) was used to quantify extrapyramidal signs. Furthermore, all subjects underwent a standardized clinical psychiatric examination including the Mini-Mental State Examination (MMSE) for dementia. For practical reasons, all assessments and MRI scans were carried out in the onphase to minimize movement artifacts due to tremor. All volunteers had a normal neurological and neuropsychological examination as well as tested negative for mutations in the Parkin gene. All subjects and patients gave their informed written consent for participation in this study, which was approved by the local ethics committee. 3 ) were assessed on a 1.5T scanner (Siemens, Symphony, Erlangen, Germany). Morphometric analysis was performed on a voxel-by-voxel basis using SPM2 software (FIL, London, UK, www.fil.ion.ucl.ac.uk/spm). Details of the VBM procedure are described elsewhere. 19 Categorical comparisons were calculated between sPARKIN-MC, iPD patients, and their corresponding control group. Since we hypothesized that the severity and the duration of the disease is accompanied by reduced GMV, in a second step, simple regression analyses between morphometric data and clinical scores were performed using the SPM regression algorithms. Because our a priori hypothesis predicted structural changes in the striatum and the globus pallidus (GP), these regions were used as region-of-interest using the WFU-PickAtlas (ANSIR, Wake Forest University) 20 as anatomical reference. Given our a priori hypothesis the statistical threshold of P < 0.005 (uncorrected) was executed for the regions of interest. For the whole brain volume the statistical threshold was set at positive false discovery rate (pFDR) < 0.05 after correction.
RESULTS
All sPARKIN-MC and iPD patients were clinically affected with Parkinsonism. There was no significant age difference between the sPARKIN-MC and iPD patients and their control groups (P 5 0.80). There was no dementia in any group. The mean UPDRS-III score of the sPARKIN-MC was 22.7 6 4.5 and 22.7 6 3.3 in iPD patients. There was no significant difference between these two groups (P 5 0.98) and there was also no significant difference regarding the affected side in the PD patients groups. Mean disease duration, defined 
FIG. 1. Structural changes in the basal ganglia in sPARKIN-MC and iPD patients. A:
The categorical comparison revealed a decrease (orange) of GMV in the left caudate in sPARKIN-MC and a mild increase (blue) in the right globus pallidus externus in sPARKIN-MC and in the right putamen iPD patients. B: Simple regression analysis with the UPDRS-III score in sPARKIN-MC (orange) displayed a mild GMV decrease in the putamen bilaterally and in the right caudate. In the iPD group (blue) the GMV decrease was most prominent in the right putamen. C: In sPARKIN-MC (orange) the GMV were decreased in the caudate and putamen bilaterally in the simple regression analysis with the disease duration, whereas in the iPD group (blue) the greatest GMV decrease was found in the right putamen again; the left putamen was however slightly affected.
as time from symptom onset, was 13.7 6 3.2 years in sPARKIN-MC and 12.1 6 1.0 years in iPD patients. There was also no significant difference between these two groups of patients (P 5 0.59) ( Table 1) . Analysis of variance (Fig. 1A, Table 2 ) revealed a slight increase in GMV in the right globus pallidus externus (GPe) adjacent to the right putamen in sPAR-KIN-MC relative to their controls. The relative GMV increase was smaller in symptomatic patients compared with the increases that we had previously found in asymptomatic PARKIN-MC. 19 However, the more predominant finding was a reduction in GMV in the head of the left caudate nucleus and right putamen in sPAR-KIN-MC and to a lesser extent also in the left caudate in iPD patients. These findings were verified in the following regression analyses.
Simple regression analysis (Fig. 1B ,C, Table 2 ) was used to test for linear changes in GMV with UPDRS-III score or disease duration. In sPARKIN-MC, the GMV in both the putamina and the right caudate decreased significantly with the UPDRS-III score. In addition, the head of the caudate nucleus and the putamen showed a bilateral decrease in GMV with disease duration. In iPD patients predominantly the right putamen showed a linear decrease in GMV with the UPDRS-III score and with disease duration.
DISCUSSION
Using VBM, that is capable of discovering subtle, regionally specific changes in GMV, we found two major differences in the pathoanatomic patterns in the basal ganglia in genetically determined and iPD patients. First, the results confirmed our hypothesis that at the symptomatic stage in both genetically determined and idiopathic PD, the basal ganglia are subject to a progressive atrophy, which gradually increases with severity and duration of symptoms in PD. However, in the context of our recent results in asymptomatic heterozygous PARKIN-MC, 19 the possibly residual, slight increase of putaminal and GPe GMV in both groups of PD patients may indicate remaining compensatory mechanisms. Second, although both groups of patients showed basal ganglia alterations in GMV in the categorical comparisons and relative decreases in GMV associated with the UPDRS-III score or disease duration as revealed by the regression analyses, the regional expression of disease-related atrophy was not similar. These findings show structural differences between symptomatic PARKIN-MC and patients with iPD that may reflect clinical and metabolic findings in these groups as identified in previous studies.
In more detail, the clinical regression analyses between the individual values of the UPDRS-III and disease duration and the morphometric data revealed a strong negative correlation with the basal ganglia. Previous MR-morphometric studies in iPD patients showed inconsistent results: The GMV of the basal ganglia was shown to be either normal [11] [12] [13] [14] or (partly) decreased 15, 16, 18, 21 in iPD patients compared to controls. These discrepant structural findings may be due to different usage of methodology (MRI-based volumes or region of interest analysis [VOI/ROI], VBM) and differences in the severity and duration of the disease of the investigated PD population.
The observation that the severity and the duration of the disease are accompanied by striatal GMV changes may indicate a dynamically developing process in the striatum. In the context of our hypothesis of compensation for the basal ganglia dysfunction, the atrophy may now reflect parts of a ''decompensation process,'' resulting in the loss of basal ganglia GMV [15] [16] [17] [18] and the appearance of clinical symptoms. Although the presence of a basal ganglia atrophy in PD patients is still a matter of controversy, [11] [12] [13] [14] it is conceivable given the increasing intensity of the nigro-striatal degeneration in PD. 19 This is in accordance with postmortem studies showing a loss of striatal neurons in PD patients. 22, 23 The more symmetrically distributed pattern of degeneration in sPARKIN-MC corresponds to previous PET findings showing a symmetric reduction in putaminal 18 F-DOPA-uptake 7, 8, 10 and preferentially bilateral manifestation of symptoms in sPARKIN-MC. 1, 3 The differential pattern in sPARKIN-MC may be attributed to the slower progression of PD symptoms and a longer presymptomatic course of the disease, which may produce different degenerative and adaptive changes in the basal ganglia tissue.
As already suggested for the presymptomatic period in aPARKIN-MC, 19 we assume that the partially increased basal ganglia GMV in iPD and sPARKIN-MC indicates a possible active compensatory mechanism for the chronic dopaminergic deficit resulting in basal ganglia dysfunction. 7, 9 Therefore, we propose that presynaptic dopaminergic basal ganglia dysfunction in sPARKIN-MC and iPD patients leads initially to a chronic increase in neuronal activity within the basal ganglia and an increase in GMV of the hyperactive structures. This increase in GMV might represent a long-term consequence of adaptive plasticity in the striatum that allows for a compensation of the dopaminergic deficit in the striatal motor circuit still present after the occurrence of symptoms. Although the exact nature of the structural changes in the basal ganglia remains to be elucidated, our morphometric findings suggest a dynamic development of structural changes during the course of PD.
